MOUNTAIN VIEW , CA, UNITED STATES, January 7, 2026 /EINPresswire.com/ -- Renaissance Healthcare for Women, led by ...
Urogynecologist Judy Yeh, MD, FACOG and the Tift Regional Medical Center operating room team conducted the first Altaviva ...
Market OverviewThe global ostomy devices market is projected to grow at a healthy rate of 4–5% and is expected to reach approximately USD 3.2 billion by 2026. This steady expansion is driven by rising ...
CystoSmart™, an AI software tool for bladder tumor detection in patients undergoing screening and surveillance endoscopic examination of the bladder is brand agnostic and compatible with flexible and ...
A woman's decades-long struggle with incontinence was finally solved when doctors discovered a rare condition.
TipRanks on MSN
Relmada’s BOOST phase 3 bladder cancer trial sets up a new catalyst for RLMD investors
Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...
This guide deconstructs the pathophysiology of UTIs, exploring the anatomical risks in women, and the efficacy of antibiotic ...
The first new antibiotic for UTIs in nearly 30 years has been approved by regulators. Gepotidacin, also known as Blujepa, is ...
St. Bernards Healthcare has implanted Arkansas’s first Altaviva™ tibial nerve device, offering a minimally invasive, anesthesia-free solution for overactive bladder and urge urinary incontinence.
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, consistent release of chemotherapy proved far more effective than traditional ...
Which bladder control underwear are best? There are many problems that people suffer from that cause more than physical harm. According to the Urology Care Foundation, approximately 33 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback